dr. reddy's labs glp-1 receptor agonist medications Laboratories has entered the fast-growing therapy segment with the launch of its semaglutide generic, Obeda, for Type 2 diabetes in India's ₹1,446 crore market. 𝐑𝐞𝐚𝐝 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐨𝐧 𝐨𝐮𝐫 A Comprehensive Review of the

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management

Clear role: high-efficacy anchor therapy with adherence advantages

Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight

Within the first seven days, youll feel it working!*

This process preserves the full molecular spectrum of saffron, including volatile compounds like safranal, which are often lost during conventional extraction methods.Its content is 10 times higher in safranal and 20 times more concentrated in crocins than standard extracts, enhancing the effects of saffron on emotional balance